Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

West Pharmaceutical Services Inc / Equity Bottom-Up

<ul><li>West Pharmaceutical Services, a globally recognized leader in innovative solutions for injectable drug administration, reported a strong start to the year 2024, despite several challenges in the market.</li><li>The firm recorded a slight decrease in organic sales, operating profits and diluted EPS compared to Q1 2023 due to market dynamics, primarily inventory adjustments, and customer destocking, which is the reduction of excess inventory held by customers.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

West Pharmaceutical Services, a globally recognized leader in innovative solutions for injectable drug administration, reported a strong start to the year 2024, despite several challenges in the market.The firm recorded a slight decrease in organic sales, operating profits and diluted EPS compared to Q1 2023 due to market dynamics, primarily inventory adjustments, and customer destocking, which is the reduction of excess inventory held by customers.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

West Pharmaceutical Services: Contract Manufacturing Expansion & Other Major Drivers

<ul><li>West Pharmaceutical Services recently held its fourth quarter 2023 earnings conference call, closely examining their financial results, providing an update on their business operations, and presenting an overview of their financial outlook for the full year of 2024.</li><li>The company reported a significant base growth in 2023, which offset a decrease of COVID-19-related sales by about $320 million.</li><li>This growth was mainly driven by expanding customer demand for the company's high value product offerings and their contract manufacturing services.</li></ul>

West Pharmaceutical Services recently held its fourth quarter 2023 earnings conference call, closely examining their financial results, providing an update on their business operations, and presenting an overview of their financial outlook for the full year of 2024.The company reported a significant base growth in 2023, which offset a decrease of COVID-19-related sales by about $320 million.This growth was mainly driven by expanding customer demand for the company's high value product offerings and their contract manufacturing services.

West Pharmaceutical Services: Regulatory Shift Driving Increased Demand for High Value Products! - Major Drivers

<ul><li>West Pharmaceutical Services Inc. delivered a mixed set of results for the previous quarter, with revenues well below analyst expectations but managed earnings beat.</li><li>The third quarter saw impressive organic net sales growth despite a significant year-over-year decline in COVID-19-related sales.</li><li>However, as the quarter progressed, specific large customers started managing their safety stocks, which led West Pharmaceutical Services to adjust its organic sales growth for the upcoming quarter.</li></ul>

West Pharmaceutical Services Inc. delivered a mixed set of results for the previous quarter, with revenues well below analyst expectations but managed earnings beat.The third quarter saw impressive organic net sales growth despite a significant year-over-year decline in COVID-19-related sales.However, as the quarter progressed, specific large customers started managing their safety stocks, which led West Pharmaceutical Services to adjust its organic sales growth for the upcoming quarter.

West Pharmaceutical Services Inc.: Why Is The Capacity Expansion Required? - Major Drivers

<ul><li>West Pharmaceutical Services delivered mixed results for the previous quarter, with revenues below the analyst consensus.</li><li>Sales price increases provided $43.1 million or 5.6 percentage points of growth in the quarter.</li><li>The base Proprietary goods business expanded by the mid-teens and was the main driver of the second quarter achievement.</li></ul>

West Pharmaceutical Services delivered mixed results for the previous quarter, with revenues below the analyst consensus.Sales price increases provided $43.1 million or 5.6 percentage points of growth in the quarter.The base Proprietary goods business expanded by the mid-teens and was the main driver of the second quarter achievement.

West Pharmaceutical Services: What Is Their Biggest Competitive Advantage? - Major Drivers

Equity Capital Markets

West Pharmaceutical Services Inc / Equity Capital Markets

<ul><li>This is our first report on West Pharmaceutical Services, a major manufacturer of injectable medication delivery and packaging systems.</li><li>West Pharmaceutical reported an all-around beat in its last result and generated about 8% growth in organic sales overall.</li><li>With COVID-19 excluded, West anticipates that its base organic sales growth was in the low double digits, with proprietary product growth in the mid-teens.</li></ul>

This is our first report on West Pharmaceutical Services, a major manufacturer of injectable medication delivery and packaging systems.West Pharmaceutical reported an all-around beat in its last result and generated about 8% growth in organic sales overall.With COVID-19 excluded, West anticipates that its base organic sales growth was in the low double digits, with proprietary product growth in the mid-teens.

West Pharmaceutical Services Inc.: Initiation of Coverage – Business Strategy & Key Drivers

United States

West Pharmaceutical Services, Inc. applies value-added services to the process of bringing new drug therapies and healthcare products to global markets. The Company's technologies include the design and manufacture of packaging components, research and development of drug delivery systems, and contract laboratory services and other services.

West Pharmaceutical Services Inc (WST US)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

West Pharmaceutical Services Inc (WST US)

West Pharmaceutical Services: Contract Manufacturing Expansion & Other Major Drivers

West Pharmaceutical Services, a globally recognized leader in innovative solutions for injectable drug administration, reported a strong start to...

Baptista Research

West Pharmaceutical Services: Regulatory Shift Driving Increased Demand for High Value Products! - Major Drivers

West Pharmaceutical Services recently held its fourth quarter 2023 earnings conference call, closely examining their financial results, providing...

Baptista Research

West Pharmaceutical Services Inc.: Why Is The Capacity Expansion Required? - Major Drivers

West Pharmaceutical Services Inc. delivered a mixed set of results for the previous quarter, with revenues well below analyst expectations but...

Baptista Research

West Pharmaceutical Services: What Is Their Biggest Competitive Advantage? - Major Drivers

West Pharmaceutical Services delivered mixed results for the previous quarter, with revenues below the analyst consensus. Sales price increases...

Baptista Research

West Pharmaceutical Services Inc.: Initiation of Coverage – Business Strategy & Key Drivers

This is our first report on West Pharmaceutical Services, a major manufacturer of injectable medication delivery and packaging systems. West...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)